English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/103752
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Squalene Synthase As a Target for Chagas Disease Therapeutics

AuthorsShang, N.; Li, Q.; Ko, T.-P.; Chan, H.-C.; Li, J.; Zheng, Y.; Huang, C.-H.; Ren, F.; Chen, C.-C.; Zhu, Z.; Galizzi, M.; Li, Z.-H.; Rodrigues-Poveda, C. A.; González-Pacanowska, D.; Veiga-Santos, P.; de Carvalho, T.M.U.; de Souza, W.; Urbina, J.A.; Wang, A.H.-J.; Docampo, R.; Li, K.; Liu, Y.-L.; Oldfield, E.; Guo, R.-T.
Issue Date2014
PublisherPublic Library of Science
CitationPLoS Pathogens 10 (2014)
AbstractTrypanosomatid parasites are the causative agents of many neglected tropical diseases and there is currently considerable interest in targeting endogenous sterol biosynthesis in these organisms as a route to the development of novel anti-infective drugs. Here, we report the first x-ray crystallographic structures of the enzyme squalene synthase (SQS) from a trypanosomatid parasite, Trypanosoma cruzi, the causative agent of Chagas disease. We obtained five structures of T. cruzi SQS and eight structures of human SQS with four classes of inhibitors: the substrate-analog S-thiolo-farnesyl diphosphate, the quinuclidines E5700 and ER119884, several lipophilic bisphosphonates, and the thiocyanate WC-9, with the structures of the two very potent quinuclidines suggesting strategies for selective inhibitor development. We also show that the lipophilic bisphosphonates have low nM activity against T. cruzi and inhibit endogenous sterol biosynthesis and that E5700 acts synergistically with the azole drug, posaconazole. The determination of the structures of trypanosomatid and human SQS enzymes with a diverse set of inhibitors active in cells provides insights into SQS inhibition, of interest in the context of the development of drugs against Chagas disease. © 2014 Shang, et al.
URIhttp://hdl.handle.net/10261/103752
DOIhttp://dx.doi.org/10.1371/journal.ppat.1004114
Identifiersdoi: 10.1371/journal.ppat.1004114
issn: 1553-7374
Appears in Collections:(IPBLN) Artículos
Files in This Item:
File Description SizeFormat 
Squalene_Na_Shang.pdf4,94 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.